Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Operating Expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — operating expenses of $25.59M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses changed year-over-year?
- Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses increased by 39.7% year-over-year, from $18.32M to $25.59M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses?
- Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses has grown at a 7.5% compound annual growth rate (CAGR), from $84.36M to $97.49M.
- What does gyre pharmaceuticals — operating expenses mean?
- This is the aggregate of all costs incurred to maintain the segment's daily operations, excluding the cost of goods sold. It provides a comprehensive view of the total burn rate or operational overhead required to sustain the segment's business activities.